Table 3 Results of the cost per response analysis at 16, 24, and 52 weeks
Outcome | Parameter | Week | Overall | Secukinumab | Ustekinumab | Adalimumab originator | Ixekizumab |
|---|---|---|---|---|---|---|---|
PASI 75 | Number of evaluated patients (N) | 16 | 405 | 165 | 118 | 38 | 49 |
24 | 380 | 154 | 105 | 46 | 38 | ||
52 | 551 | 241 | 145 | 63 | 65 | ||
Response rate (%) | 16 | 86% | 95% | 80% | 74% | 90% | |
24 | 90% | 97% | 87% | 83% | 89% | ||
52 | 91% | 93% | 94% | 87% | 91% | ||
Cost per responder ratio (€) | 16 | €9774 | €9015 | €11,689 | €7848 | €11,092 | |
24 | €11,652 | €10,982 | €13,617 | €10,069 | €13,710 | ||
52 | €20,281 | €19,932 | €21,387 | €18,491 | €22,084 | ||
PASI 90 | Number of evaluated patients (N) | 16 | 391 | 162 | 113 | 36 | 46 |
24 | 362 | 150 | 95 | 45 | 35 | ||
52 | 540 | 238 | 140 | 62 | 63 | ||
Response rate (%) | 16 | 59% | 64% | 56% | 50% | 63% | |
24 | 74% | 84% | 69% | 67% | 71% | ||
52 | 75% | 77% | 74% | 71% | 81% | ||
Cost per responder ratio (€) | 16 | €14,378 | €13,395 | €16,806 | €11,560 | €15,839 | |
24 | €14,213 | €12,742 | €17,035 | €12,477 | €17,172 | ||
52 | €24,662 | €23,978 | €27,522 | €22,755 | €24,743 | ||
PASI 100 | Number of evaluated patients (N) | 16 | 421 | 172 | 123 | 38 | 52 |
24 | 393 | 158 | 107 | 48 | 40 | ||
52 | 564 | 243 | 150 | 66 | 65 | ||
Response rate (%) | 16 | 36% | 42% | 29% | 32% | 37% | |
24 | 46% | 51% | 38% | 56% | 53% | ||
52 | 53% | 55% | 51% | 52% | 58% | ||
Cost per responder ratio (€) | 16 | €23,350 | €20,079 | €32,031 | €18,312 | €27,129 | |
24 | €22,674 | €20,857 | €30,779 | €14,784 | €23,268 | ||
52 | €35,045 | €33,419 | €39,280 | €31,378 | €34,289 |